4th Quarter - Report
ZIRKELBACH STRATEGIES for AMAG PHARMACEUTICALS
Client
Income
$75,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Pharmaceutical issues related to womens health product access
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARY KATHLEEN ZIRKELBACH | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| COVIS HOLDCO S.AR.L. | Luxembourg | Luxembourg | 100.0% | — |
| APOLLO OVERSEAS PARTNERS (892 AIV) IX, L.P. | Cayman Islands | Cayman Islands | 23.5% | — |
| COVIS GROUP S. A R.L. | Luxembourg | Luxembourg | 100.0% | — |
| COVIS MIDCO 1 S.A R.L. | Luxembourg | Luxembourg | 100.0% | — |
| AP IX (EURO AIV) L.P. | Cayman Islands | Cayman Islands | 42.1% | — |
| COVIS TOPCO S.A R.L. | Luxembourg | Luxembourg | 100.0% | — |
| COVIS FINCO S.A R.L. | Luxembourg | Luxembourg | 100.0% | — |
| COVIS EQUITYCO SCA | Luxembourg | Luxembourg | 100.0% | — |
| COVIS PHRMA GMBH | Switzerland | Switzerland | — | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.